{"groups":[{"description":"Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"FG000","title":"Cohort A (Lenalidomide, Dexamethasone)"},{"description":"Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"FG001","title":"Cohort B (Lenalidomide, Dexamethasone)"},{"description":"Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"FG002","title":"Cohort C (Lenalidomide, Dexamethasone, Pomalidomide)"},{"description":"Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"FG003","title":"Cohort D (Lenalidomide, Dexamethasone, Pomalidomide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}